Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR3-TACC3 fusion
i
Other names:
FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3, TACC3, Transforming acidic coiled-coil containing protein 3, ERIC-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2261
;
10460
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
FGFR3 overexpression (11)
TACC3 expression (4)
FGFR3 expression (2)
FGFR2 underexpression + FGFR3 overexpression (1)
FGFR3 positive (1)
FGFR2 underexpression + FGFR3 expression (0)
FGFR3 overexpression (11)
TACC3 expression (4)
FGFR3 expression (2)
FGFR2 underexpression + FGFR3 overexpression (1)
FGFR3 positive (1)
FGFR2 underexpression + FGFR3 expression (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR3-TACC3 fusion
Glioblastoma
FGFR3-TACC3 fusion
Glioblastoma
anlotinib
Sensitive: C3 – Early Trials
anlotinib
Sensitive
:
C3
anlotinib
Sensitive: C3 – Early Trials
anlotinib
Sensitive
:
C3
FGFR3-TACC3 fusion
Gallbladder Cancer
FGFR3-TACC3 fusion
Gallbladder Cancer
Debio 1347
Sensitive: C3 – Early Trials
Debio 1347
Sensitive
:
C3
Debio 1347
Sensitive: C3 – Early Trials
Debio 1347
Sensitive
:
C3
FGFR3-TACC3 fusion
Urothelial Cancer
FGFR3-TACC3 fusion
Urothelial Cancer
infigratinib
Sensitive: C3 – Early Trials
infigratinib
Sensitive
:
C3
infigratinib
Sensitive: C3 – Early Trials
infigratinib
Sensitive
:
C3
FGFR3-TACC3 fusion
Urothelial Cancer
FGFR3-TACC3 fusion
Urothelial Cancer
Debio 1347
Sensitive: C3 – Early Trials
Debio 1347
Sensitive
:
C3
Debio 1347
Sensitive: C3 – Early Trials
Debio 1347
Sensitive
:
C3
FGFR3-TACC3 fusion
Glioblastoma
FGFR3-TACC3 fusion
Glioblastoma
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR3-TACC3 fusion
Non Small Cell Lung Cancer
FGFR3-TACC3 fusion
Non Small Cell Lung Cancer
infigratinib
Sensitive: C3 – Early Trials
infigratinib
Sensitive
:
C3
infigratinib
Sensitive: C3 – Early Trials
infigratinib
Sensitive
:
C3
FGFR3-TACC3 fusion
Non Small Cell Lung Cancer
FGFR3-TACC3 fusion
Non Small Cell Lung Cancer
ponatinib
Sensitive: C3 – Early Trials
ponatinib
Sensitive
:
C3
ponatinib
Sensitive: C3 – Early Trials
ponatinib
Sensitive
:
C3
FGFR3-TACC3 fusion
Gastric Cancer
FGFR3-TACC3 fusion
Gastric Cancer
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
FGFR3-TACC3 fusion
Urothelial Cancer
FGFR3-TACC3 fusion
Urothelial Cancer
ARQ 087
Sensitive: C3 – Early Trials
ARQ 087
Sensitive
:
C3
ARQ 087
Sensitive: C3 – Early Trials
ARQ 087
Sensitive
:
C3
FGFR3-TACC3 fusion
Glioma
FGFR3-TACC3 fusion
Glioma
anlotinib
Sensitive: C4 – Case Studies
anlotinib
Sensitive
:
C4
anlotinib
Sensitive: C4 – Case Studies
anlotinib
Sensitive
:
C4
FGFR3-TACC3 fusion
Adrenal Cortex Carcinoma
FGFR3-TACC3 fusion
Adrenal Cortex Carcinoma
erdafitinib
Sensitive: C4 – Case Studies
erdafitinib
Sensitive
:
C4
erdafitinib
Sensitive: C4 – Case Studies
erdafitinib
Sensitive
:
C4
FGFR3-TACC3 fusion
Astrocytoma
FGFR3-TACC3 fusion
Astrocytoma
ABSK091
Sensitive: C4 – Case Studies
ABSK091
Sensitive
:
C4
ABSK091
Sensitive: C4 – Case Studies
ABSK091
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.